Bayer, J&J in frame for bigger anti-clotting market opportunity

FRANKFURT, Aug 27 (Reuters) – Bayer and Johnson &Johnson’s blockbuster clot prevention drug Xarelto wasshown to cut the risk of potentially deadly strokes and heartattacks in patients with severe atherosclerosis by 24 percent,raising the prospects of billions more in sales.
The post Bayer, J&J in frame for bigger anti-clotting market opportunity appeared first on RocketNews | Top News Stories From Around the Globe.